The utility of early gestational OGTT and biomarkers for the development of gestational diabetes mellitus: an international prospective multicentre cohort study

早期妊娠口服葡萄糖耐量试验和生物标志物在妊娠期糖尿病发生发展中的应用价值:一项国际前瞻性多中心队列研究

阅读:1

Abstract

AIMS/HYPOTHESIS: There is no clear consensus regarding accurate risk stratification in early pregnancy for later developing gestational diabetes mellitus (GDM). Therefore, this study aims to evaluate the predictive performance of an OGTT and several biomarkers in the first trimester of pregnancy. Their association with insulin action, beta cell function and requirement for insulin were additionally assessed. METHODS: In this prospective cohort study, we included 657 pregnant women in six Central European centres. Patient history and anthropometric data were obtained, a blinded 75 g OGTT was performed and biochemical markers were assessed at a median gestational age of 13.4 weeks (IQR 12.7-14.1). Another OGTT was performed in later pregnancy to identify women with GDM. A detailed investigation of glucose homeostasis was performed at both visits in a subgroup of women. RESULTS: Eighty-three women (12.6%) developed GDM. Progression to GDM was fairly well predicted by glucose concentrations during the early OGTT in terms of areas under the receiver operating characteristic curves (OGTT glucose at fasting: 0.68; OGTT glucose at 60 min: 0.74; OGTT glucose at 120 min: 0.72). Some biomarkers showed significant but modest predictive accuracy. Early gestational OGTT glucose concentrations were further associated with impaired insulin sensitivity and beta cell dysfunction, as well as the requirement for insulin in later pregnancy. CONCLUSIONS/INTERPRETATION: Although the accurate diagnosis of GDM before 24 weeks remains an ongoing discussion, dynamically assessed glucose concentrations during an early OGTT were closely associated with impaired glucose homeostasis and showed good predictive accuracy for later development of GDM as well as the requirement for insulin. These findings may be used to develop a protocol to distinguish between low- and high-risk mothers. Trial registration ClinicalTrials.gov NCT02035059.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。